Key stats
About WisdomTree BioRevolution Fund
Expense ratio
0.45%
Home page
Inception date
Jun 3, 2021
WDNA provides exposure to developed market companies that will be significantly transformed by innovations in genetics and biotechnology over the medium- and long-term. Firms that meet size and liquidity screens must generate at least 50% of its revenue from the following BioRevolution sectors (as determined by Dr. Jamie Metzl): a) human health, b) consumer products, c) agriculture and food, d) materials, chemicals and energy, and e) biological machines and interfaces. Applicable financial filings are used to identify and evaluate eligible companies. The Index Committee will then determine the final list of holdings which are reconstituted and rebalanced semi-annually to a modified equal weighting. Although the fund launched with health care sector tilts, WDNA expects to have increased exposure to other related industries over the long-term because of the constant reinforcing of tech advancements in the genetics and biotechnology field.
Classification
What's in the fund
Exposure type
Health Technology
Process Industries
Stock breakdown by region